

## GenSight Biologics to Present at Upcoming Investor Conferences

**Paris, France, January 4, 2023, 7:30 am CET** – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company will participate in the following investor conferences in January 2023:

### **26<sup>th</sup> ODDO BHF Forum**

*January 9 - 10, 2023 - Virtual*

**Bernard Gilly**, Co-Founder & Chief Executive Officer, and **Thomas Gidoïn**, Chief Financial Officer, will host investor meetings.

### **Invest Securities Biomed Forum**

*January 24, 2023 - Paris, France*

**Thomas Gidoïn**, Chief Financial Officer, will attend in person and host investor meetings.

### **11<sup>th</sup> Degroof Petercam Healthcare Conference**

*January 25, 2023 - Virtual*

**Thomas Gidoïn**, Chief Financial Officer, will host investor meetings.

### **Contacts**

#### **GenSight Biologics**

Corporate Communications Director  
Clothilde Caillet  
[ccaillet@gensight-biologics.com](mailto:ccaillet@gensight-biologics.com)

#### **RooneyPartners**

Media Relations  
Jeanene Timberlake  
[jtimberlake@rooneypartners.com](mailto:jtimberlake@rooneypartners.com)  
+1 646-770-8858

#### **LifeSci Advisors**

Investor Relations  
Guillaume van Renterghem  
[gvanrenterghem@lifesciadvisors.com](mailto:gvanrenterghem@lifesciadvisors.com)  
+41 (0)76 735 01 31

#### **Orpheon Finance**

Retail Investors  
James Palmer  
[j.palmer@orpheonfinance.com](mailto:j.palmer@orpheonfinance.com)  
+33 (0)7 60 92 77 74

### **About GenSight Biologics**

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is an investigational compound and has not been registered in any country at this stage; a marketing authorization application is currently under review by the EMA for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

